Cardinal Health, Inc. (CAH)
|Net Income (ttm)||1.14B|
|Ex-Dividend Date||Dec 31, 2021|
|Day's Range||47.54 - 48.40|
|52-Week Range||45.85 - 62.96|
|Price Target||57.31 (+19.1%)|
|Earnings Date||Nov 9, 2021|
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products... [Read more...]
Financial PerformanceFinancial Statements
According to 15 analysts, the average rating for CAH stock is "Hold." The 12-month stock price forecast is 57.31, which is an increase of 19.15% from the latest price.
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Great companies trading at cheap prices? Yes, please.
SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in onco...
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain f...
Cardinal Health's (CAH) business introduces new offering for clinical labs that can enable them to focus on patient care.
DUBLIN, Ohio, Nov. 18, 2021 /PRNewswire/ -- Cardinal Health today announced its business, WaveMark™ Supply Management and Workflow Solutions, will now be available for implementation in clinical labs ac...
A Washington state trial against McKesson Corporation (NYSE: MCK), Cardinal Health Inc (NYSE: CAH), and AmerisourceBergen Corp (NYSE: ABC) for the U.S. opioid epidemic is slated to kick off today, Reute...
Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.
Cardinal (CAH) delivered earnings and revenue surprises of -2.27% and 5.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (NYSE: CAH) reported Q1 FY22 adjusted EPS of $1.29, down from $1.51 a year ago, missing the Street estimate of $1.33. Q1 sales increased 13% Y/Y to $44 billion, beating the consensus est...
DUBLIN, Ohio, Nov. 9, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2022 revenues of $44.0 billion, an increase of 13% from the first quarter of last year. Fi...
DUBLIN, Ohio, Nov. 4, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4908 per share. The dividend will be payable on Jan...
DUBLIN, Ohio, Nov. 4, 2021 /PRNewswire/ -- Biologics are the fastest growing class of drugs in the U.S.; they bring innovative, life-changing treatments to patients with cancer and chronic diseases. Due...
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #POCUS--Exo (pronounced “echo”) is expanding its board of directors and adding key industry leaders to take POCUS ultrasound imaging everywhere.
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ohio, Oct. 28, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has been awarded a $750,000 contract by the U.S. Food and Drug Administration (FDA) to implement an 18-month re...
DUBLIN, Ohio, Oct. 25, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today its cancer screening offerings from FUJIFILM Healthcare Americas Corporation and Polymedco that can be done either...
Cardinal Health's (CAH) company, OptiFreight Logistics', recent collaboration with Journey Biosciences to help patients with respect to long-term diabetes care.
Journey Biosciences and Cardinal Health OptiFreight® Logistics Collaborate to Improve Long-Term Diabetes Care
LEBANON, N.H., Oct. 14, 2021 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company with an innovative proactive diagnostic screening technology for high risk kidney complications, including...
DUBLIN, Ohio, Oct. 12, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today its Strategic Stock Solution now serves nearly 40 hospitals and health systems nationwide, just one year after its...
New Cardinal Health survey explores how rheumatologists are managing current industry dynamics including changing rei...
DUBLIN, Ohio, Oct. 6, 2021 /PRNewswire/ -- While demand for rheumatology care continues to grow, rheumatologists are feeling pressured by reimbursement changes, administrative duties and workforce short...